InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,978.27
(
1.72%
)

Replies to post #69475 on Biotech Values

Replies to #69475 on Biotech Values

DewDiligence

12/04/08 4:54 PM

#69477 RE: genisi #69475

This protocol does not adhere to the design that ITMN CEO Dan Welch spoke of on a recent webcast (#msg-33497987).

Welch had said that Roche would test the two drugs in varying dose ratios. However, all of the cohorts in the actual trial use a 10:3 ratio of total daily R7128 to total daily ITMN-191.

ghmm

12/04/08 4:55 PM

#69478 RE: genisi #69475

Nice find thanks! I don't see what is being done in cohort C (vs b & d).

to be off topic a little I saw a poster about Naglazyme A Follow-Up of Enzyme Replacement Therapy in Two MPS VI Patients with Poorly Engrafted Bone Marrow
Transplantation. I thought BMT was not an option for MPS VI. A little more research and I found it is an option in some do you know how common? Am I right in thinking BMT is not an option in Morquio too. TIA!